SWSophia Brismar Wendel

Sophia Brismar Wendel

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Sophia Brismar Wendel has a total of 129 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Can metformin prolong pregnancy in preterm pre-eclampsia? Study protocol for a Nordic multicentre randomised placebo-controlled trial (PI4)

    by Pia Gudmundsson, Catherine Anne Cluver, Anna Sandström, Linda Lindström, Simon Timpka, Susanne Hesselman, Caroline Lilliecreutz, Sophia Brismar Wendel, Emma Von Wowern, Karolina Linden, et al.

    Pre-eclampsia affects 2–8% of all pregnancies and remains a leading cause of maternal and perinatal morbidity and mortality. A randomised trial in South Africa suggested metformin used to treat preterm pre-eclampsia (26–32 weeks’ gestation) may prolong pregnancy by 7 days compared with standard care. However, this finding was borderline significant and requires validation in higher-resource settings and in diverse populations. Here, we present a Nordic multicentre trial protocol designed to evaluate whether extended-release metformin can prolong gestation in women with preterm pre-eclampsia. Pre-eclampsia Intervention 4 trial is a phase III, double-blind, multicentre randomised controlled trial conducted in Sweden, Norway and Finland aiming to investigate whether metformin can prolong gestation in preterm pre-eclampsia. A total of 294 women between 22+0 and 33+6 weeks of gestation with pre-eclampsia and planned to undergo expectant management will be enrolled. Participants are randomised to receive one gram of extended-release metformin or matching placebo three times daily. The primary outcome is prolongation of gestation defined as time from randomisation to birth. Secondary outcomes include length of neonatal hospital stay and neonatal birth weight. Adverse events will be reported in line with current clinical trial guidelines. All efficacy analyses will be conducted according to the intention-to-treat principle. The trial is conducted in accordance with Good Clinical Practice, as defined by the International Council for Harmonisation. The protocol, including amendments, was approved by the Swedish Ethical Review Authority and the Swedish Medical Products Agency in accordance with national legislation, and authorised for Finland and Norway through the Clinical Trials Information System in accordance with the EU Clinical Trials Regulation. Results will be disseminated at international conferences and published in peer-reviewed journals and communicated via popular science outlets, media, patient organisations and the trial website: https://www.preeclampsiaresearch.com/pi-trials. NCT06033131.

  • Open Access

    Induction of labor after one previous cesarean: Time for the MIBAC trial

    by Sophia Brismar Wendel, Tove Wallström

  • Open Access

    Routine external aortic compression versus no aortic compression in elective caesarean delivery to reduce blood loss: study protocol of a randomised controlled trial

    by Helena Grobecker, Mårten Alkmark, Ola Andersson, Sandra Bergendahl, Annika Carlson, Amanda Fagerkrantz, Anette Hein, Susanne Hesselman, Ulrika Johannesson, Ove Karlsson, et al.

    Introduction: External aortic compression is used to reduce excessive blood loss in childbirth. However, it has never been evaluated for the prevention of postpartum haemorrhage. This study aims to investigate whether routine external aortic compression, in patients undergoing elective caesarean delivery, is an effective and acceptable preventive method to reduce severe postpartum haemorrhage. Methods and analysis: This multicentre, randomised, controlled, open-label trial aims to enrol 2246 patients across 10 maternity hospitals in Sweden. Patients with a live single or multiple pregnancy after 34 complete gestational weeks undergoing elective caesarean delivery will be randomised to either routine manual external aortic compression or no aortic compression (standard care). The primary objective is to investigate whether external aortic compression in caesarean delivery is an effective preventive method to reduce severe postpartum haemorrhage, defined as a calculated blood loss >1000 mL or blood transfusion within 48 hours. The secondary objectives are to investigate whether it reduces overall maternal morbidity, shortens time in surgery or hospital, affects patient-reported outcomes and is safe and acceptable to patients. Analyses will follow the intention-to-treat (ITT) principle, using generalised linear mixed-effects models for the primary and secondary outcomes with adjustment for study centre. Multiplicity for confirmatory outcomes will be controlled using a hierarchical testing procedure. Ethics and dissemination: Ethical approval was obtained on 20 September 2022 from the Swedish Ethical Review Authority (2022-04327-01), and amendments were approved on 28 November 2022 (2022-06377-02), 17 February 2025 (2025-00700-02) and 9 June 2026 (2026-03503-02). Results of the study will be published in peer-reviewed medical journals, presented at scientific meetings and communicated to the public through mass media. Trial registration number: NCT05312658 .

  • Open Access

    The OPTION trial: outpatient induction of labour – study protocol for a prospective, non-inferiority, multicentre randomised controlled trial

    by Verena Sengpiel, Heléne Sangskär, Ulla-Britt Wennerholm, Helen Elden, Kristina Gemzell-Danielsson, Sofie Graner, Tove Wallström, Susanne Hesselman, Magnus Domellöf, Maria Jonsson, et al.

    Introduction: Sweden, as many other high-income countries, has adopted guidelines to offer induction of labour at 41+0 gestational weeks to decrease the risk for perinatal death. As more than 20% of the pregnant population reach this gestational age, and along with other contributing factors, induction rates have increased up to 30% in many countries. Both women and care providers have raised the question if outpatient induction could be a convenient, safe and economic alternative, reducing the burden on inpatient care in maternity hospitals. Before introducing outpatient induction into clinical routine, studies need to assure safety for the child and woman as well as efficacy of the method. Method and analysis: A register-based randomised controlled multicentre non-inferiority trial to study if outpatient induction in low-risk inductions is (1) as safe for the child (perinatal composite of mortality and morbidity) and (2) as effective (proportion of vaginal deliveries) as inpatient induction at the hospital. Secondary outcomes are further health outcomes, experiences of pregnant women, partners and care providers, health economics and future pregnancy outcome. Participating women with a singleton pregnancy and unripe cervix between 37+0 and 41+6 gestational weeks planned for low-risk induction will undergo induction of labour with either a balloon catheter or oral misoprostol according to clinical practice at the study site and the woman’s informed choice. Randomisation will allocate women to either outpatient (home or patient hotel) or inpatient induction (standard care). Women undergoing outpatient induction can remain at home for up to 2 days, with an assessment after 24 hours including cardiotocography. Once active labour ensues, all women will receive standard care in the hospital. The assessment of non-inferiority will involve a two-sided 95% CI and 80% power, requiring randomisation of 8891 women to ensure a probability of at least 0.80 that the upper limit of a two-sided 95.7% CI for a difference in the primary safety outcome is below the non-inferiority margin of 1.5%. 31 of the 45 delivery units in Sweden are currently recruiting. Data will be collected from the electronic case report form and Swedish healthcare registers. Questionnaire and qualitative interview-based studies will be performed to explore experiences of pregnant women, partners and care providers. Additionally, a health economic evaluation will be performed. Ethics and dissemination: The Swedish Ethical Review Authority approved the study (3 June 2020; 2020-02675 with amendments 2021-03045, 2022-00865-02, 2023-01252-02, 2024-00560-02, 2024-2024-04597-02). The Swedish Medical Products Agency approved the study for the medication arm (25 August 2020, EudraCT number: 2020-000233-41; 5.1-2020-60240 with amendments 5.1-2022-73500, 5.1-2023-630). Due to changed regulation, in 2023, the study medication arm was transferred and approved by the European Medicines Agency (23 October 2023, EU CT Number: 2023-507164-39-00; CTIS 5.1.2-2023-099775 with amendments 5.1.2-2024-081916, 5.1.2-2025-036291). The Swedish Medical Products Agency approved the study for the medical device arm (6 April 2021, CIV-ID: CIV-20-09-034712; 5.1-2021-14812 with amendments 5.1-2022-14252, 5.1-2023-596, 5.1-2024-8886, 5.1-2024-55554). The medical device arm was transferred to Regulation (EU) 2017/745 (23 December 2024, 5.1-2025-24242 and amendment 5.1-2025-6050). The study will involve more than 80% of all delivery units in Sweden, which will allow for a smooth implementation of any new routine after the study’s conclusion. Results will be published in relevant scientific journals, presented at national and international conferences, and communicated to participants and relevant institutions through the Outpatient Induction study homepage ( www.optionstudien.se ), the webinars of the Swedish Network for National Clinical Studies in Obstetrics and Gynecology ( www.snaks.se ) as well as social and public media. Trial registration number: EudraCT No: 2020-000233-41, after transfer to the European Medicines Agency EU CT Number: 2023-507164-39-00; CIV-ID 20-09-034712.


  • Open Access

    Episiotomy: Are we ready to let women make choices in pregnancy and childbirth?

    by Sandra Bergendahl, Sophia Brismar Wendel

    It is important to work with care providers’ knowledge and perceptions about research on pregnant women to enable patients to make informed choices


  • Top Cited Papers
    Open Access

    Lateral episiotomy or no episiotomy in vacuum assisted delivery in nulliparous women (EVA): multicentre, open label, randomised controlled trial

    by Sandra Bergendahl, Maria Jonsson, Susanne Hesselman, Victoria Ankarcrona, Åsa Leijonhufvud, Anna-Carin Wihlbäck, Tove Wallström, Emmie Rydström, Hanna Friberg, Helena Kopp Kallner, et al.

    Objective To assess the effect of lateral episiotomy, compared with no episiotomy, on obstetric anal sphincter injury in nulliparous women requiring vacuum extraction. Design A multicentre, open label, randomised controlled trial. Setting Eight hospitals in Sweden, 2017-23. Participants 717 nulliparous women with a single live fetus of 34 gestational weeks or more, requiring vacuum extraction were randomly assigned (1:1) to lateral episiotomy or no episiotomy using sealed opaque envelopes. Randomisation was stratified by study site. Intervention A standardised lateral episiotomy was performed during the vacuum extraction, at crowning of the fetal head, starting 1-3 cm from the posterior fourchette, at a 60° (45-80°) angle from the midline, and 4 cm (3-5 cm) long. The comparison was no episiotomy unless considered indispensable. Main outcome measures The primary outcome of the episiotomy in vacuum assisted delivery (EVA) trial was obstetric anal sphincter injury, clinically diagnosed by combined visual inspection and digital rectal and vaginal examination. The primary analysis used a modified intention-to-treat population that included all consenting women with attempted or successful vacuum extraction. As a result of an interim analysis at significance level PResults From 1 July 2017 to 15 February 2023, 717 women were randomly assigned: 354 (49%) to lateral episiotomy and 363 (51%) to no episiotomy. Before vacuum extraction attempt, one woman withdrew consent and 14 had a spontaneous birth, leaving 702 for the primary analysis. In the intervention group, 21 (6%) of 344 women sustained obstetric anal sphincter injury, compared with 47 (13%) of 358 women in the comparison group (P=0.002). The risk difference was −7.0% (96% CI −11.7% to −2.5%). The risk ratio adjusted for site was 0.47 (96% CI 0.23 to 0.97) and unadjusted risk ratio was 0.46 (0.28 to 0.78). No significant differences were noted between groups in postpartum pain, blood loss, neonatal outcomes, or total adverse events, but the intervention group had more wound infections and dehiscence. Conclusions Lateral episiotomy can be recommended for nulliparous women requiring vacuum extraction to significantly reduce the risk of obstetric anal sphincter injury. Trial registration ClinicalTrials.gov NCT02643108.


  • Open Access

    Pelvic floor dysfunction after intervention, compared with expectant management, in prolonged second stage of labour: A population‐based questionnaire and cohort study

    by Sandra Bergendahl, Anna Sandström, Hongwei Zhao, Jonathan M. Snowden, Sophia Brismar Wendel

    Objective: To investigate the effect of vacuum extraction (VE) or caesarean section (CS), compared with expectant management, on pelvic floor dysfunction (PFD) 1–2 years postpartum in primiparous women with a prolonged second stage of labour.Design: A population‐based questionnaire and cohort study.Setting: Stockholm, Sweden.Population: A cohort of 1302 primiparous women with a second stage duration of ≥3 h, delivering from December 2017 to November 2018.Methods: The 1‐year follow‐up questionnaire from the Swedish National Perineal Laceration Register was distributed 12–24 months postpartum. Exposure was VE or CS at 3–4 h or 4–5 h, compared with expectant management.Main outcome measures: Pelvic floor dysfunction was defined as at least weekly symptoms of urinary incontinence, pelvic organ prolapse or a Wexner score of ≥4. The risk of PFD was calculated using Poisson regression with robust variance estimation, presented as crude and adjusted relative risks (RRs and aRRs) with 95% confidence intervals (95% CIs). The implication of obstetric anal sphincter injury (OASI) on pelvic floor disorders was investigated through mediation analysis.Results: In total, 35.1% of women reported PFD. Compared with expectant management, the risk of PFD was increased after VE at 3–4 h (aRR 1.33, 95% CI 1.06–1.65) and 4–5 h (aRR 1.34, 95% CI 1.05–1.70), but remained unchanged after CS. The increased risk after VE was not mediated by OASI.Conclusions: Pelvic floor dysfunction was common in primiparous women after a prolonged second stage, and the risk of PFD increased after VE but was unaffected by CS, compared with expectant management. If a spontaneous vaginal delivery eventually occurred, allowing an extended duration of labour did not increase the risk of PFD.


  • Open Access

    Key outcomes in childbirth: Development of a perinatal core outcome set for management of labor and delivery at or near term

    by Julia Savchenko, Malin Asp, Marie Blomberg, Charlotte Elvander, Anna Hagman, Cecilia Pegelow Halvorsen, Pelle Lindqvist, Maria Nelander, Béatrice Skiöld, Sophia Brismar Wendel

    Introduction: Consistency and relevance of perinatal outcome measures are necessary basics for obstetric research, audit, and clinical counseling. Still, there is an unwarranted variation in reported perinatal outcomes, which impairs research synthesis, validity, and implementation, as well as clinical benchmarking and longitudinal comparisons. The aim of this study was to develop a short‐term perinatal (fetal and neonatal) Core Outcome Set to be used in research and quality assurance of management of labor and delivery at or near term.Material and methods: The methods were guided by the Core Outcome Measures in Effectiveness Trials Initiative Handbook. The project was prospectively registered on July 2, 2020 in the Core Outcome Measures in Effectiveness Trials (COMET) data base (reference number 1593). A list of potential outcomes was created based on a systematic review of studies evaluating interventions for peripartum management at or near term (≥34 weeks of gestation), including decisions regarding timing and type of onset of labor, intrapartum care, and mode of delivery. The list was entered into a two‐round Delphi survey with predefined consensus criteria. Participants (n = 67) included clinicians, researchers, lay persons with experience of childbirth (patient representatives), and other stakeholders. A consensus meeting was held to reach a final agreement.Results: Response rates were 82.1% (55/67) and 92.7% (51/55) for the first and second Delphi rounds, respectively. In total, 17 outcomes were included in the final core outcome set, reflecting mortality, health or morbidity, including asphyxia, central nervous system status, infection, neonatal resuscitation and admission, breastfeeding and mother‐infant interaction, operative delivery due to fetal distress, as well as birthweight and gestational age. Two of these outcomes were suggested by patient representatives.Conclusions: The Swedish Perinatal Core Outcome Set (SPeCOS) study involved a broad circle of relevant stakeholders and reached consensus on a minimal set of perinatal outcomes that should be collected and reported in a standardized way in all future studies on management of labor and delivery at or near term, regardless of the specific population or condition studied. This could improve obstetric research, evidence synthesis, uptake, implementation, and adherence, as well as clinical practice, audit, and comparisons in childbirth care.


  • Open Access

    The association between episiotomy or OASIS at vacuum extraction in nulliparous women and subsequent prelabor cesarean delivery: A nationwide observational study

    by Sophia Brismar Wendel, Can Liu, Olof Stephansson

    Introduction: Severe perineal injuries at childbirth affect women's postnatal health, including future childbirths. First births with vacuum extraction carry an increased risk of obstetric anal sphincter injuries (OASIS). Lateral or mediolateral episiotomy at vacuum extraction may decrease the risk of OASIS. Our aim was to assess whether lateral or mediolateral episiotomy, or OASIS, at vacuum extraction in nulliparous women is associated with prelabor cesarean delivery in the subsequent childbirth.Material and methods: This is a nationwide observational study using data from the Swedish Medical Birth Register, including women having a first birth with vacuum extraction and a second birth in 2000–2014. Both births were live, single, cephalic, ≥34 gestational weeks without malformations. The association between episiotomy or OASIS in the first birth and prelabor cesarean delivery in the second birth was examined using univariate and multivariate logistic regression with inverse probability of treatment weighting, and interaction analysis. Main outcome measure was prelabor cesarean delivery in the second birth.Results: In total, 44 656 women with vacuum extraction at their first birth were included. The rate of prelabor cesarean delivery in the second birth was 5.9% (824 of 13 950) in women with episiotomy, compared with 6.0% (1830 of 30 706) in women without episiotomy. Thus, women with episiotomy did not have an increased risk of prelabor cesarean delivery (adjusted odds ratio [aOR] 1.00, 95% confidence interval [95% CI] 0.83–1.20) compared with women without episiotomy. For comparison, the rate of prelabor cesarean delivery in the second birth was 20.6% (1275 of 6176) in women with OASIS, compared with 3.6% (1379 of 38 480) in women without OASIS (aOR 6.57, 95% CI 5.97–7.23). There was no interaction between episiotomy and OASIS.Conclusions: Lateral or mediolateral episiotomy at vacuum extraction in nulliparous women did not increase the risk of prelabor cesarean delivery in the subsequent childbirth. OASIS increased the odds of prelabor cesarean delivery more than sixfold.